Raising Awareness, Research and Education for Schizencephaly and other rare neurological disorders
We Are R.A.R.E., INC. is a 501(c)(3) company that is comprised of a group of non paid board members including parents, medical and legal advisers who volunteer their time to reach out globally to advocate for rare a brain disorder Schizencephaly and prevention.
We collectively set up events and community support & professional education programs throughout the year to help with our efforts.
We educate the medical world as well as families by providing resources and information and transition into this diagnosis. From conventions to training classes We Are RARE is dedicated to getting as much information to prevent, assist with therapy ideas and advocate for this unique disorder.
Founded in 2009 by a mother with a child affected by this disorder, We Are RARE Inc. has been able to set a day of awareness and reach media attention that is helping make this disorder known. Many children and adults facing this rare disorder deal with life threatening health issues including uncontrollable seizures, bone deformity, low vision, and surgeries throughout life. These bright smiles from our little warriors remind us that anything is possible with encouragement and support.
For more information: firstname.lastname@example.org
Current BBB Labs News
XeIGHT Labs, Inc. is pleased to announce that it has entered into an agreement with NuCannaCo Science Limited (NSX:NCS) to be 100% acquired, as well as its subsidiaries
January, 22 2018 – Denver, Colorado – XeIGHT LABS, INC (the “Company” or “XeIGHT)”), a leading research and private label manufacturer specializing in the development of advanced bioactive Nutraceuticals, plant-derived “Phyto-Ceuticals” and other wellness products, is pleased to announce that on January 23, 2018, the Company entered into an agreement with NuCannaCo Science Limited (NSX:NCS) to be 100% acquired – including its subsidiaries Boulder Botanical Bioscience Laboratories, Inc.; X8 Brands, LLC; Colorado Call Centers, LLC; and Flatirons Fulfilment, LLC – for US$34,615,385 in stock and US$5,200,000 in cash.
In addition, the Company has closed a $5,000,000 bridge financing which will be retired upon completion of the NuCannaCo acquisition merger. The Company will use the funds for its planned manufacturing expansion, ingredient production integration and working capital. A secondary capital raise planned by NuCannaCo is expected to provide a minimum of $13,000,000 in additional working capital at the close of the merger.
NuCannaCo Science Limited is an Australia Company (ACN 607 604 513) with operations in the US through its wholly owned US subsidiary NuCannaCo Systems, Inc. The merger will provide the Company with manufactured and marketed products produced from Hemp as well as research and development capacity for new products and technologies.
Robert Di Marco, CEO of the Company, stated, “The merger will position XeIGHT to be the leader in global manufacturing and aggressively assist our growth plan to be the largest specialized non-psychoactive cannabis company in the world. Further, the current IP portfolio and product line coupled with this merger will strengthen the XeIGHT’s market presence and facilitate its objective to become completely vertically integrated, providing turn-key GMP standard solutions for the industry”.
Argelia “Maruchy” Lachance, COO of the Company, the first female COO in the Canna-Biz publicly traded marketplace stated, “The merger fulfills XeIGHT’s long-term goals of manufacturing and marketing cannabinoids for health and wellness.”
Adam Selkin, of SLee 3 Consulting, advisor on the merger, an industry pioneer in the area of Cannabis consulting and finance, believes “This combination of companies [XeIGHT and its subsidiaries] is the best vehicle in the cannabis industry, ready for the public markets, that I’ve seen in my years as an active consultant to the industry.”
Established in 2012, XeIGHT Labs, Inc. and its subsidiaries, are a vertically integrated manufacturing, packaging, marketing, distribution and merchant processing business with a wide range of health and wellness, nutritional, nutraceutical, dietary supplement, sports nutrition, pet nutrition and skin care products.
For three years, XeIGHT and its subsidiary, Boulder Botanical Bioscience Laboratories, (BBB) have applied their extensive experience and success in the nutraceutical space to the hemp/Cannabinoid market to become a clear leader in the hemp space.
“NuCannaCo’s Board of Directors believes there is a clear value by merging of the business of NuCannaCo and XeIGHT and its subsidiaries, and that combining the entities coupled with the capital for growth gives a significant competitive edge and forms the foundation for NuCannaCo to become the largest company in the hemp cannabinoids market,” says David Goughnour, CEO of NuCannaCo Systems, Inc. and Managing Director of NuCannaCo Science Limited.
About XeIGHT Labs Inc. and its Subsidiaries
XeIGHT and BBB manufacture, distribute, market and participate in each part of the value chain for both its proprietary products as well as for third-parties for which XeIGHT manufactures and markets its products through private label, contract manufacturing, online sales, and brick and mortar sales, as well as through a variety of top tier partnerships in distribution, network advertising agencies, specialty distribution companies and media partners for radio and television.
Investor Information Contact:
- Mr. Adam Selkin: Adam@NuCannaCo.com
- Mr. David Goughnour: David@NuCannaCo.com
- Join Us on Facebook
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.